News

Nerviano Medical Sciences establishes its Scientific Advisory Board

Nerviano, IT and Boston, Mass, 26 March, 2024 – Nerviano Medical Sciences S.r.l. (NMS), and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS S.r.l., focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced the formation of their Scientific Advisory Board (SAB), with the […]

Nerviano Medical Sciences S.r.l. to present data on its platform of payload linkers for ADC conjugation at the World ADC Summit 2024 in London, UK (March 12th-15th, 2024)

Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud to announce its participation to the World ADC 2024 summit that will be held in London, UK (World ADC Europe) from March 12th to March 15th, 2024, with […]

Nerviano Medical Sciences received European Medicines Agency (EMA) Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia

NERVIANO, IT and BOSTON, Mass, 4 March, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that European […]

Nerviano Medical Sciences received Orphan Drug Designation for its next-generation FLT3 inhibitor NMS-03592088 for treatment of Acute Myeloid Leukemia

NERVIANO, IT and BOSTON, Mass, 9 January, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc. (NMS-US), a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced that the […]

Iktos and Nerviano Medical Sciences S.r.l Announce Collaboration in Artificial Intelligence for New Drug Discovery

NERVIANO Italy and PARIS France, January 8, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, and Nerviano Medical Sciences S.r.l (NMS), a leading Italian clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, today announced a collaboration agreement in AI for unprecedented kinase project. As per […]

Nerviano Medical Sciences S.r.l.’s Landmark Article in The Journal of Organic Chemistry

Nerviano Medical Sciences Srl (NMS) is pleased to announce the publication of the hot-off-the-press article “Photocatalytic Radical Coupling of Organoborates with α-Halogenated Electron-Poor Olefins” published in The Journal of Organic Chemistry (https://doi.org/10.1021/acs.joc.3c02386) .   The paper reports the unprecedented light-mediated construction of elaborated α-halo-derivatives, useful intermediates in organic synthesis. This brilliant achievement was accomplished by […]

Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate

NERVIANO and MILAN, Italy, December 14, 2023 – Nerviano Medical Sciences S.r.l. (NMS), a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A. (ITF), a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate (PDC). Under the terms of the agreement, ITF will use NMS’s […]

Share this page

Facebook
Twitter
LinkedIn
Email
svg.e-font-icon-svg {display:none!important} .elementor-button-icon {display:none!important} .show-more, .show-more2 {display:none!important} img.pf-large-image.pf-primary-img.flex-width.pf-size-full.blockImage { display: none!important; }